Outlook

2008 Financial outlook

UCB expects 2008 to again be a year of progress in the execution of UCB's strategy and of substantial investment in the company's future growth.

Revenue is expected to decrease to approximately EUR3.4 billion due, in substantial part, to the patent expiry of Zyrtec® and the expected start of generic competition to Keppra® in the USA along with further expected currency deterioration. Notwithstanding incremental marketing & selling expenses in connection with product launches and pre-launch activities, operating expenses should be slightly lower as a result of the continued cost containment efforts.

Recurring EBITDA for the full year 2008 is expected to reach approximately EUR650 million.

Net Profit is expected to exceed EUR100 million in 2008.

At the end of March, UCB announced the recall of its anti-Parkinson's drug Neupro® from the US market and of certain batches in Europe which led to an out-of stock situation in the US. Considering the resolution timeline and risk mitigation of this issue is still undetermined, the full effect on UCB's business is not yet known. Therefore, UCB's 2008 financial outlook is under review. UCB expects an update on this situation at the time of its half year reporting on August 1, 2008.